Top in ID: ‘Negative Fauci effect’; doxycycline for STI prevention
Click Here to Manage Email Alerts
After many infectious disease fellowship programs went unfilled on the latest Match Day, physicians in the field shared why they think the area has recently become more undesirable than in previous years.
“We do hard work in ID that is often underfunded and underappreciated by the health care system, but many value the substantial meaning that comes with caring for a vulnerable patient or finding strategies to curb a pandemic,” Darcy A. Wooten, MD, MS, associate professor of medicine and director of the ID fellowship training program at the University of California, San Diego, said.
It was the top story in infectious disease last week.
Another top story examined the different impacts of taking doxycycline after unprotected sex for STI prevention in men who have sex with men (MSM), transgender women and cisgender women.
Read these and more top stories in infectious disease below:
‘Negative Fauci effect’? ID reckons with disappointing Match Day
As the COVID-19 pandemic grew, so did the feeling that the field of ID might begin to attract more physicians, drawn by the important and rewarding work that was so suddenly in the public eye. Read more.
Doxycycline continues to show promise for STI prevention, but not in cisgender women
Studies continue to show that taking doxycycline after having unprotected sex can prevent STIs in transgender women and MSM. What has been unclear is whether it also works for cisgender women. Read more.
Early data indicate flu vaccine offered significant protection
Preliminary estimates published in MMWR and presented by the CDC indicate that this season’s influenza vaccine offered significant protection among all ages. Read more.
Do ID physicians have a good quality of life?
Physicians have cited overwork and burnout as contributing factors making it difficult to recruit physicians for a career in infectious diseases. Read more.
Long-acting HIV regimen a ‘game changer’ preferred by most patients
Long-acting cabotegravir plus rilpivirine administered every 2 months was noninferior to daily oral HIV medication and was preferred by most participants in a phase 3b randomized trial, data show. Read more.